Full Text

Turn on search term navigation

© 2012. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Cerebral ischemia was induced using photothrombosis 1 hour after intraperitoneal injection of the p38 mitogen-activated protein kinase (MAPK) inhibitor SB239063 into Swedish mutant amyloid precursor protein (APP/SWE) transgenic and non-transgenic mice. The number of surviving neurons in the penumbra was quantified using Nissl staining, and the activity of p38 MAPKs was measured by western blotting. The number of surviving neurons in the penumbra was significantly reduced in APP/SWE transgenic mice compared with non-transgenic controls 7 days after cerebral ischemia, but the activity of p38 MAPKs was significantly elevated compared with the non-ischemic hemisphere in the APP/SWE transgenic mice. SB239063 prevented these changes. The APP/SWE mutation exacerbated ischemic brain injury, and this could be alleviated by inhibiting p38 MAPK activity. Abbreviations AD, Alzheimer′s disease; Aβ, beta amyloid; MAPKs, mitogen activated protein kinases; APP/SWE, Swedish mutant amyloid precursor protein

Details

Title
Inhibiting p38 mitogen-activated protein kinase attenuates cerebral ischemic injury in Swedish mutant amyloid precursor protein transgenic mice
Author
Zou, Liangyu 1 ; Qin, Haiyan 1 ; He, Yitao 1 ; Huang, Heming 1 ; Lu, Yi 1 ; Chu, Xiaofan 1 

 Department of Neurology, Shenzhen People′s Hospital, Second Clinical College, Jinan University, Shenzhen 518020, Guangdong Province 
Pages
1088-1094
Publication year
2012
Publication date
May 2012
Publisher
Medknow Publications & Media Pvt. Ltd.
ISSN
16735374
e-ISSN
18767958
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2382809190
Copyright
© 2012. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.